Tumors of GI system Flashcards Preview

GI pharm > Tumors of GI system > Flashcards

Flashcards in Tumors of GI system Deck (42)
Loading flashcards...
1

Drugs used for anal cancer

cisplatin, mitomycin, 5FU

2

Drugs used for CRC

bevacizumab, capecitabine, cetuximab, 5FU

3

Drugs used for esophageal cancer

Cisplatin, Docetaxel, 5FU

4

Drugs used for gastric cancer

cisplatin, docetaxel, 5FU, trastuzumab

5

Drugs used for GI carcinoid

octreotide, interferon

6

Drugs used for GIST

imatinib, sunitinib

7

Drugs used for pancreatic cancer

5FU, erlotinib, gemcitabine

8

Drugs used for liver cancer

5FU

9

What is 1st/2nd line therapy for esophageal cancer?

Cisplatin + 5FU. docetaxel is 2nd line

10

How should you determine gastic cancer therapy

Check Her2 status. If positive, trastuzumab should be added to 5FU/cisplatin therapy

11

How do you determine CRC therapy?

Capecitbine or 5FU + bevacizumab or cetuximab unless KRAS +

12

What drug is associated with tachyphylaxis?

octreotide- duration of treatment is 12 months usually

13

Treatment with conventional chemo is GIST is futile due to ____.

overexpression of P-gp

14

GIST can be categorized into what groups?

KIT-mutant (80%), KIT negative, PDGFRA-mutant, wild-type

15

MOA bevacizumab

rhuMAab-VEGF

16

Bevacizumab issues

bleeding, perforation, wound dehisence, HTN

17

Capecitabine MOA

5FU prodrug

18

Capecitabine issues

DPD deficiency prevents metabolic activation. CI in renal dysfunction. Adverse CV events. Neuro and heme toxicities

19

Cetuximab MOA

EGFR Ab

20

Cetuximab issues

Cardiac arrest, respiratory arrest, sudden death, acneiform, infusion rxn

21

Cisplatin MOA

DNA crosslinks and adducts

22

Cisplatin issues

ototoxicity, NEPHROTOXICITY, BMS

23

Docetaxel MOA

Stabilize microtubule

24

Docetaxel issues

Increased tx related morality in NSCLC; edema, neuropathy, CI in hepatic disease, DLT: neutropenia

25

Erlotinib MOA

EGFR-TKI

26

Erlotinib issues

GI tox, bleeding, LFTs, ocular toxicities, rarely ILD

27

5FU MOA

pyrimidine antimetabolite that inhibits TS and interferes with RNA synthesis and effects DNA

28

5Fu issues

DPD deficiency = enhanced neurotoxicity, severe heme tox and BMS

29

Gemcitabine MOA

DNA polymerase inhibitor, incorporates triphosphate

30

Gemcitabine issues

BMS, infection, sensory peripheral neuropathy, arthralagia, drowsiness, anorexia resolves in 2-3 days

31

imatinib MOA

TKI adjuvant with resection of KIT mutant GIST

32

Imatinib issues

GI tox, CHF, neuro tox, fluid retention, edema

33

Inf-a MOA

enzyme activation following cell surface receptor binding and TK activation

34

inf-a issues

neuropsychiatric events, FLS

35

Mitomycin MOA

alkylating agent

36

Mitomycin issues

BMS, thrombocytopenia, leukopenia, HUS

37

Octreotide MOA

SS, reduce duodenal bicarb, amylase, gastric acidity, gallbladder contractility, bile secretion, inhibits meal induced increases in SMA and portal venous blood flow

38

Octreotide issues

monitor blood glucose, dose-related diarrhea

39

Sunitinib MOA

inhibitor of >80 RTKs

40

Sunitinib issues

Thrombocytopenia, bleeding, QT prolongation, GI complications including perforation

41

Trastuzumab MOA

HER2-neu antibody. Inhibition of Her2--> accumulation of cdk inhibitor p26--> cell cycle arrest. Inhibits constitutive Her2 shedding by MP (correlate with clinical activity)

42

Trastuzumab issues

LVEF dysfunction, cardiomyopathy, anaphylaxis, angioedema, pulmonary toxicity